Expert Opinion on Managing Adverse Reactions Associated With Acalabrutinib Therapy: A Delphi Consensus From France

•This study aimed to establish consensus-based guidance for managing acalabrutinib-associated AEs in patients with CLL.•Hospital pharmacists should analyze drug interactions before starting acalabrutinib therapy.•Acalabrutinib should not be used with strong CYP3A inhibitors or inducers due to risks...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2024-10
Hauptverfasser:	Ysebaert, Loïc, Ederhy, Stéphane, Leblond, Véronique, Malartre, Stéphanie, Portalier, Anaïs, Sibaud, Vincent, Tomowiak, Cécile, Zerbit, Jérémie
Format:	Artikel
Sprache:	eng
Schlagworte:	Acalabrutinib Adverse events Clinical management Consensus DELPHI
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!